Meet the company reprogramming the future of synthetic biology

April 14, 2021 | Published on Forbes

Florian-Schuster-Rick-Klausner-Mark-Kotter-Forbes-Apr2021-v3

bit.bio Co-founder and CFO Florian Schuster, investor and Lyell founder, Rick Klausner, and bit.bio founder and CEO Mark Kotter

 

John Cumbers, founder and CEO of SynBioBeta, published a piece in Forbes after a conversation with Dr Rick Klausner – bit.bio investor, founder and Executive Chairman of Lyell Immunopharma – and Dr Mark Kotter, bit.bio founder and CEO.

The piece covers how Rick and Mark first met and how bit.bio is reimagining what is possible with the engineering of mammalian cells – industrial-scale cell manufacturing and bringing sustainable cell-culture meats to consumers via Meatable.

 
Mark showed up at Lyell and started showing me his beautiful data. I walked out and told my assistant to cancel the morning. It only took four hours for us to decide to write him a check.
Dr Rick Klausner

bit.bio investor, founder and Executive Chairman of Lyell Immunopharma

 
By converting current cell therapies, which at the moment cost hundreds of thousands of dollars, to a model of biologics or perhaps even a small molecule in the future, cell therapies could become common and widespread.
Mark Kotter

CEO and founder, bit.bio

 

Read the full article here.